1. A single centre experience of first-line pembrolizumab in stage IV non-small-cell lung cancer (NSCLC). (January 2019) Authors: Denslow, R.; Yarde, A.; Brunner, C.; Walther, J.; Botten, J.; Jankowska, P. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A single centre experience of pembrolizumab combination therapy in untreated advanced non-squamous non-small-cell lung cancer (NSCLC). (January 2020) Authors: Cox, N.; Walther, J.; Botten, J.; Jankowska, P. Journal: Lung cancer Issue: Volume 139(2020)Supplement 1 Page Start: S56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Nail toxicity in a patient being treated with immune checkpoint inhibitors. (January 2019) Authors: Botten, J.; Jankowska, P.; Walther, J.; Yarde, A. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗